H.R.806 - To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

Loading Bill Text
Rollover any line of text to comment and/or link to it.

A project of the Participatory Politics Foundation and the Sunlight Foundation
U.S. Congress - Text of H.R.806 as Introduced in House To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authoriz...A non-profit, non-partisan public resource
Everyone can be an insider. Learn how.Use the options to the right to narrow down your search results.
Sessions:
112th CongressSearch in:
The easiest way to email your members of Congress
Donate Now
Rollover any line of text to comment and/or link to it.
HR 806 IHCommentsClose CommentsPermalink
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.CommentsClose CommentsPermalink
Mrs. EMERSON (for herself, Mr. BERRY, Mr. WAMP, and Mr. MOORE of Kansas) introduced the following bill; which was referred to the Committee on Energy and CommerceCommentsClose CommentsPermalink
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.CommentsClose CommentsPermalink
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,CommentsClose CommentsPermalink
Section 505 of the Federal Food, Drug, and Cosmetic Act (
`(o) Prohibition of Authorized Generic Drugs-CommentsClose CommentsPermalink
`(1) IN GENERAL- Notwithstanding any other provision of this Act, no holder of a new drug application approved under subsection (c) shall manufacture, market, sell, or distribute an authorized generic drug, direct or indirectly, or authorize any other person to manufacture, market, sell, or distribute an authorized generic drug.CommentsClose CommentsPermalink
`(2) AUTHORIZED GENERIC DRUG- For purposes of this subsection, the term `authorized generic drug'--CommentsClose CommentsPermalink
`(A) means any version of a listed drug (as such term is used in subsection (j)) that the holder of the new drug application approved under subsection (c) for that listed drug seeks to commence marketing, selling, or distributing, directly or indirectly, after receipt of a notice sent pursuant to subsection (j)(2)(B) with respect to that listed drug; andCommentsClose CommentsPermalink
`(B) does not include any drug to be marketed, sold, or distributed--CommentsClose CommentsPermalink
`(i) by an entity eligible for exclusivity with respect to such drug under subsection (j)(5)(B)(iv); orCommentsClose CommentsPermalink
`(ii) after expiration or forfeiture of any exclusivity with respect to such drug under such subsection (j)(5)(B)(iv).'.CommentsClose CommentsPermalink
OpenCongress is a free and open-source project of the Participatory Politics Foundation, a 501(c)3 non-profit organization with a mission to increase civic engagement. The non-profit Sunlight Foundation is the Founding and Primary Supporter of OpenCongress.